Sorrento Therapeutics, Inc. (SRNE)

Market Cap	271.86K
Revenue (ttm)	64.27M
Net Income (ttm)	-548.00M
Shares Out	543.71M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,403,499
Average Volume	361,932
Open	0.310
Previous Close	0.305
Day's Range	0.301 - 0.340
52-Week Range	0.161 - 3.090
Beta	1.68
RSI	38.65
Earnings Date	n/a

About Sorrento Therapeutics

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 949
• Stock Exchange: OTCMKTS
• Ticker Symbol: SRNE

Financial Performance

In 2022, Sorrento Therapeutics's revenue was $62.84 million, an increase of 18.78% compared to the previous year's $52.90 million. Losses were -$572.84 million, 33.7% more than in 2021.